title: Curcumin for the Treatment of Glioblastoma.
abstract: Glioblastoma multiforme is a highly aggressive primary cancer of the brain associated with a poor prognosis. Modest increases in survival can sometimes be achieved with the use of temozolomide and radiation therapy after surgery, but second-line therapy after recurrence has a limited efficacy. Curcumin has demonstrated promising results against this form of cancer in experimental models. The reported activity of curcumin against cancer stem cells, a major cause of glioblastoma resistance to therapy, and its ability to augment the apoptotic effects of ceramides, suggest it would have a synergistic effect with cytotoxic chemotherapy agents currently used in second-line therapy, such as lomustine.
authors.affiliation: SignPath Pharma, Inc., Quakertown PA, U.S.A.
authors.forename: Laura A
authors.initials: LA
authors.lastname: Sordillo
authors.affiliation: SignPath Pharma, Inc., Quakertown PA, U.S.A.
authors.forename: Peter P
authors.initials: PP
authors.lastname: Sordillo
authors.affiliation: SignPath Pharma, Inc., Quakertown PA, U.S.A. lhelson@comcast.net.
authors.forename: Lawrence
authors.initials: L
authors.lastname: Helson
mesh_terms: D001812:Blood-Brain Barrier; D003474:Curcumin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000379:methods*; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D011379:Prognosis; D015996:Survival Rate
chemical_list: D003474:Curcumin
keywords: Glioblastoma; blood–brain barrier; cancer stem cells; ceramide; combination chemotherapy; curcumin; lipophilic agent; lomustine; review